NCT04762355View on ClinicalTrials.gov

Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

January 3, 2019

Study Completion Date

January 3, 2019

Conditions
Dry Eye Disease
Interventions
DRUG

Palovarotene

ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

DRUG

Vehicle

Placebo-to-match palovarotene ophthalmic solution vials

Trial Locations (1)

H3P 3P1

Algorithme Pharma facility, Québec

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Clementia Pharmaceuticals Inc.

INDUSTRY